MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal CancerPhase II study of mFOLFOX6-BV vs. FOLFIRI-BV in mCRC
- Publication date
- 15 May 2019
- Publisher
- eScholarship, University of California